UCB (OTCMKTS:UCBJF) Shares Gap Down – What’s Next?

UCB SA (OTCMKTS:UCBJF) shares gapped down before the market opened on Wednesday . The stock had previously closed at $290.74, but opened at $277.6250. UCB shares last traded at $277.6250, with a volume of 6 shares.

Analyst Ratings Changes

UCBJF has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of UCB in a research report on Monday, December 8th. Morgan Stanley restated an “overweight” rating on shares of UCB in a report on Monday, September 8th. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat, UCB currently has an average rating of “Buy”.

UCB Stock Down 4.5%

The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The company’s fifty day moving average is $278.69 and its 200-day moving average is $246.34.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.